BEIGENE SWITZERLAND GMBH

Patent Applications and Registrations

Patent applications and USPTO patent grants for BEIGENE SWITZERLAND GMBH.The latest application filed is for "crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydrop- yrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof".

Company Profile

7.9.11

BEIGENE SWITZERLAND GMBH - Basel CH
BEIGENE SWITZERLAND GMBH - Zurich CH

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Trademarks

Patent Activity

Patent	Date
CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROP- YRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF App 20220281881 - WANG; Zhiwei ; et al.	2022-09-08
CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROP- YRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF App 20220274994 - WANG; Zhiwei ; et al.	2022-09-01
Anti-tigit Antibodies And Their Use As Therapeutics And Diagnostics App 20220251195 - ZHANG; Tong ; et al.	2022-08-11
Oral Solid Tablet Comprising Bruton's Tyrosine Kinase Inhibitor And Preparation Method Therefor App 20220249491 - QIU; Gang ; et al.	2022-08-11
Oral Capsule And Preparation Method Therefor App 20220241285 - WANG; Yiping ; et al.	2022-08-04
Anti-pd1 Antibodies And Their Use As Therapeutics And Diagnostics App 20220119524 - LI; Kang ; et al.	2022-04-21
Anti-PD1 antibodies and their use as therapeutics and diagnostics Grant 11,186,637 - Li , et al. November 30, 2	2021-11-30
Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators Grant 11,142,528 - Wang , et al. October 12, 2	2021-10-12
Anti-pd1 Antibodies And Their Use As Therapeutics And Diagnostics App 20210230274 - LI; Kang ; et al.	2021-07-29
CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROP- YRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF App 20210130363 - WANG; Zhiwei ; et al.	2021-05-06
Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydrop- yrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof Grant 10,927,117 - Wang , et al. February 23, 2	2021-02-23
Treatment Of Indolent Or Aggressive B-cell Lymphomas Using A Combination Comprising Btk Inhibitors App 20200368237 - HILGER; James ; et al.	2020-11-26
Anti-pd1 Antibodies And Their Use As Therapeutics And Diagnostics App 20200216535 - LI; Kang ; et al.	2020-07-09
SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS App 20200148690 - WANG; Zhiwei ; et al.	2020-05-14
Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators Grant 10,570,139 - Wang , et al. Feb	2020-02-25
Anti-PD1 antibodies and their use as therapeutics and diagnostics Grant 10,519,235 - Li , et al. Dec	2019-12-31
Anti-PD1 antibodies and their use as therapeutics and diagnostics Grant 9,988,450 - Li , et al. June 5, 2	2018-06-05

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.